Phase I study of paclitaxel (Taxol®) plus vinorelbine (Navelbine®) in patients with untreated stage IIIb and IV non-small cell lung cancer
| Autor: | A. Depierre, M. Chazard, Mariette Mercier, Jean-Luc Breton, Virginie Westeel, P. Jacoulet |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Male Pulmonary and Respiratory Medicine Cancer Research medicine.medical_specialty Lung Neoplasms Neutropenia Fever Paclitaxel medicine.medical_treatment Vinblastine Vinorelbine Gastroenterology chemistry.chemical_compound Carcinoma Non-Small-Cell Lung Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Infusions Intravenous Lung cancer Survival rate Aged Chemotherapy business.industry Middle Aged medicine.disease Survival Analysis Surgery Treatment Outcome Oncology chemistry Toxicity Female business Febrile neutropenia medicine.drug |
| Zdroj: | Lung Cancer. 31:295-301 |
| ISSN: | 0169-5002 |
| DOI: | 10.1016/s0169-5002(00)00193-8 |
| Popis: | A dose escalation study of paclitaxel in combination with vinorelbine was conducted in 21 patients with previously untreated stage IIIb or IV non-small cell lung cancer (NSCLC). All three patients treated with the initial dose of paclitaxel 135 mg/m2 administered as a 1-h intravenous infusion and vinorelbine 25 mg/m2 experienced dose-limiting toxicity (febrile neutropenia). After modification of the dosing schedule, the MTD of paclitaxel was found to be 115 mg/m2 when combined with vinorelbine 20 mg/m2 on day 1, followed by vinorelbine 20 mg/m2 on day 5. Partial responses were achieved in 24% of patients, with a median duration of response of 126 days (range from 84 to 484 days) and a 1-year survival rate of 42%. In conclusion, haematologic toxicity (febrile neutropenia/neutropenia) severely restricts the dosing schedule of combined paclitaxel and vinorelbine, and possibly limits anti-tumour efficacy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect